FindMyKOL
Clinical trialNCT02319824CompletedPhase 1Interventional

NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy

NCT02319824 is a phase 1 interventional trial sponsored by Fred Hutchinson Cancer Center. As of 21 Nov 2026, it is completed. It studies Autologous NY-ESO-1-specific CD8-positive T Lymphocytes in Sarcoma. The registry lists an enrollment of 2 participants at 1 site in 1 country. The registry lists a start date of 31 Jan 2015 and a primary completion date of 30 Jun 2015. One of its registered investigators has a FindMyKOL profile.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT02319824
FieldValue
Registry IDNCT02319824
StatusCompleted
PhasePhase 1
Study typeInterventional trial
Lead sponsorFred Hutchinson Cancer Center
Enrollment2
Registered sites1
Countries1
ConditionsSarcoma
DrugsAutologous NY-ESO-1-specific CD8-positive T Lymphocytes
Start31 Jan 2015
Primary completion30 Jun 2015
Last update posted5 Jul 2017

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This pilot, phase I trial studies the safety of cancer-testis antigen (NY-ESO-1)-specific T cells (a type of immune cell) in treating patients with NY-ESO-1-expressing sarcomas that have spread to other places in the body and are receiving palliative (relief of symptoms and suffering caused by cancer) radiation therapy. Placing a modified gene for NY-ESO-1 into white blood cells may help the body build an immune response to kill tumor cells that express NY-ESO-1. Palliative radiation therapy may help patients with advanced sarcoma live more comfortably. Giving NY-ESO-1-specific T cells following palliative radiation therapy may be a better treatment for patients with sarcomas.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Washington, United States1 site
  • Fred Hutch/university of Washington Cancer Consortium

    Seattle

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashington: 1 siteWA1MontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT02319824

Each answer restates registry values shown on this page.

What is NCT02319824?

NCT02319824 is a phase 1 interventional trial sponsored by Fred Hutchinson Cancer Center. It studies Autologous NY-ESO-1-specific CD8-positive T Lymphocytes in Sarcoma.

Who leads NCT02319824?

The registry names Seth Pollack (principal investigator, Fred Hutch/University of Washington Cancer Consortium) as the overall official.

Where does NCT02319824 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT02319824 study?

The registered drug and biological interventions are Autologous NY-ESO-1-specific CD8-positive T Lymphocytes.

When did NCT02319824 end?

The registry lists a primary completion date of 30 Jun 2015. The sponsor last updated the record on 5 Jul 2017.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.